Aquestive Therapeutics, Inc. (AQST) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $18.55M | +3.8% |
| 2024 | $17.87M | -14.2% |
| 2023 | $20.83M | +7.5% |
| 2022 | $19.39M | — |
| 2020 | $12.96M | -36.3% |
| 2019 | $20.36M | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $18.55M | +3.8% |
| 2024 | $17.87M | -14.2% |
| 2023 | $20.83M | +7.5% |
| 2022 | $19.39M | — |
| 2020 | $12.96M | -36.3% |
| 2019 | $20.36M | — |